

THE SHAREHOLDERS' MEETING OF DIASORIN S.P.A. HAS:

- AUTHORIZED THE PURCHASE OF TREASURY SHARES FOR THE PURPOSE OF REMUNERATING SHAREHOLDERS;
- APPROVED THE AMENDMENT OF ART. 5 OF THE ARTICLES OF ASSOCIATION IN ORDER TO ELIMINATE THE INDICATION OF THE UNIT VALUE OF THE SHARES;
- AUTHORIZED THE CANCELLATION OF TREASURY SHARES.

THE BOARD OF DIRECTORS APPROVED THE LAUNCH OF THE SHARE BUYBACK PLAN AIMED AT REMUNERATING SHAREHOLDERS

Saluggia, Italy – January 27, 2026 – Diasorin S.p.A. (FTSE MIB: DIA) ("Diasorin" or the "Company") announces that the Shareholders' Meeting held today under the chairmanship of Mr. Michele Denegri, with a shareholding equal to 84,16% of the voting rights, approved - in ordinary session - to authorize the purchase of treasury shares aimed at their cancellation without reduction of capital in order to remunerate shareholders. The authorization was granted up to a maximum amount of shares corresponding to a maximum total disbursement not exceeding Euro 250,000,000 and a maximum number of 4,500,000 ordinary shares (equal to 8.04% of the share capital), to be implemented also in several tranches for a period of eighteen months starting from today's resolution.

The Shareholders' Meeting also approved in extraordinary session:

- to amend art. 5 of the Articles of Association in order to eliminate the indication of the unit value of the shares;
- to authorize the cancellation of treasury shares, without reduction of the share capital, to be implemented up to a maximum total amount of 6,500,000 Diasorin shares.

For further details, please refer to the explanatory reports pursuant to Article 125-ter of Legislative Decree 58/1998 made available to the public at the Company's registered office, on the Company's website (<https://int.diasorin.com/it/>, Section "Group/Governance/Shareholders' Meeting") and on the authorised storage mechanism "eMarketStorage" (available on the www.emarketstorage.com website), as well as to the minutes of the Shareholders' Meeting which will be published within the terms of the law.

It is also announced that the Board of Directors of the Company, which met after the Shareholders' Meeting, resolved to launch a share buyback program – based on the authorization granted today and therefore aimed at remunerating shareholders – for a total disbursement not exceeding Euro 250,000,000 and up to a maximum of 4,500,000 ordinary shares, equal to approximately 8.04% of the share capital, within the term of the authorisation. In particular, it is expected that the program will be executed, within the quantities indicated above, with regard to the maximum value of Euro 185,000,000, starting from today and, with regard to a further Euro 65,000,000, after the approval of

the financial statements as at 31 December 2025 by the Shareholders' Meeting, within 18 months from today's date.

In order to implement the plan, Diasorin has appointed Bank of America as its intermediary, which will make decisions regarding purchases independently, including in relation to the timing of transactions and in compliance with daily price and volume limits and the terms of the program.

The purchases will be made in accordance with the terms and conditions established by the aforementioned shareholders' resolution, in compliance with the trading conditions provided for in Article 3 of Delegated Regulation (EU) 2016/1052 and, therefore, at a price not exceeding the higher of the price of the last independent transaction and the price of the highest current independent offer on the trading venues where the purchase is made, it being understood that the unit price may not be lower by a minimum of 10% and higher by a maximum of 5% than the official price of the Diasorin share in the stock exchange session prior to each individual purchase transaction. The share buybacks will be carried out on regulated markets, in accordance with the operating procedures established in the regulations for the organisation and management of the same, so as to ensure equal treatment between shareholders and compliance with all public disclosure obligations.

Diasorin will communicate the details of potential purchases made and any other element required by law within the terms of the law. Any subsequent changes to the aforementioned purchase programme and to the information already published will be promptly communicated by the Company.

It should also be noted that as of today the Company holds 2,947,590 treasury shares in portfolio, equal to approximately 5.27% of the share capital.

ABOUT DIASORIN

Headquartered in Italy and listed at the Italian Stock Exchange in the FTSE MIB Index, Diasorin is a global leader in the In Vitro Diagnostic (IVD) field and is active since 2021 in the Life Science business. For over 50 years, the Company has been developing, producing and marketing reagent kits used by diagnostic laboratories worldwide.

The Group operates in 5 continents through 30 companies, 4 branches, 10 manufacturing facilities and 9 research and development centers. The extensive diagnostic testing and Life Science offer, made available through continuous investments in research, positions Diasorin as the player with the broadest range of specialty tests available within the diagnostic market, and identifies the Group as the "Diagnostic Specialist".

More info at www.diasorin.com

FOR ADDITIONAL INFORMATION, PLEASE CONTACT:

INVESTOR RELATIONS

Riccardo Fava

Corporate VP Communication, ESG & Investor Relations

riccardo.fava@diasorin.com

Eugenio Ragazzo

Corporate Investor Relations & ESG Senior Analyst

eugenio.ragazzo@diasorin.com